By Staff
Wednesday, May 26, 2021 12:18 AM
MONROE, N.J.—
The International Sports Vision Association (ISVA), an interdisciplinary group of professionals dedicated to advancing the field of vision training for athletes of all ages and levels to help them achieve peak athletic performance, has announced the appointments of its new executive and advisory board members.
By Staff
Friday, February 5, 2021 12:24 AM
BOCA RATON, Fla.—
Connectyx Technologies Holdings Group, Inc., a development-stage biomedical company focusing on novel treatments for rare diseases, announced it has entered into an exclusive patent license agreement to practice inventions contained within the patent applications listed below with the
National Eye Institute.
By Staff
Thursday, October 1, 2020 12:21 AM
New York—
The American Foundation for the Blind (AFB) announced the release of the Flatten Inaccessibility research
report, the culmination of survey findings from 1,921 U.S. participants who are blind or have low vision. Of those who participated, 65 percent of participants were blind and 35 percent had low vision.
By Staff
Friday, September 11, 2020 12:15 AM
NEW YORK—With childhood myopia rising rapidly and the age of onset lowering, it’s no wonder myopia management is the hottest topic in eyecare. Learn the techniques for slowing the progression of myopia in children from this series of three free COPE-approved webinars made possible by an unrestricted grant from
CooperVision. Professor Mark Bullimore, Dr. Maria Walker and Dr. Vishakha Thakrar will present the latest evidence-based myopia knowledge to enhance your clinical and patient communication skills.
By Staff
Wednesday, September 9, 2020 12:15 AM
WASHINGTON, D.C.—
The Alliance for Eye and Vision Research (AEVR) has announced a series of virtual events on Sept. 23 that are associated with International Age-Related Macular Degeneration (AMD) Awareness Week 2020 and AEVR’s Sixth Annual Emerging Vision Scientists (EVS) Day on Capitol Hill.
By Staff
Friday, April 17, 2020 12:18 AM
MIAMI—To better understand a specific form of glaucoma, known as pseudoexfoliation glaucoma, researchers at the
Bascom Palmer Eye Institute are using cutting-edge metabolomic studies.
By Staff
Monday, February 3, 2020 12:21 AM
PALO ALTO, Calif.—
PARC, a Xerox company, announced last week that it has reached an agreement with global eyecare company
Alcon to develop innovative new treatments for eyecare. The agreement includes a licensing arrangement with Alcon to leverage PARC intellectual property for potential new products that are anticipated to enter the market over the next two to four years, according to the announcement. “Alcon has been working with PARC for more than three years to develop innovative technology that can be used with our vision care products,” Andy Pawson, president of Alcon’s Global Vision Care franchise, said.
By Staff
Friday, January 17, 2020 12:18 AM
DUBLIN—
Allergan plc (NYSE: AGN), a global pharmaceutical company with more than 70 years of heritage in eyecare, announced a partnership with Von Miller, a former Super Bowl MVP, Denver Broncos linebacker and advocate for healthy vision, to shine a light on the millions of people living with glaucoma. As an ambassador for the
“My Glaucoma” campaign, Miller will address the misunderstandings and impact of glaucoma and encourage those with the disease, and their caregivers, to take early action, according to the announcement this week. This includes going to the doctor regularly and taking medications as prescribed.
By Staff
Tuesday, January 14, 2020 12:15 AM
CAMBRIDGE, England—
Exonate, an early stage biotechnology company based here, said Monday that it has entered into a strategic collaboration agreement with
Janssen Pharmaceuticals Inc., a unit of Johnson & Johnson, that will work toward developing an eye drop treatment for retinal vascular diseases, such as Age-Related Macular Degeneration (AMD) and Diabetic Macular Oedema (DMO). The effort will focus on using mRNA targeted therapies. The agreement was facilitated by Johnson & Johnson Innovation. Exonate has developed small molecules that inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) through the selective inhibition of serine/threonine-protein kinase (SRPK1)-mediated VEGF splicing, according to the announcement.
By Staff
Wednesday, January 8, 2020 12:15 AM
PLEASANTON, Calif.—
Samsung Electronics Co. and
IrisVision, a leader in digital vision technologies and maker of the world's first smart, wearable vision-assistive device, announced a strategic partnership to roll out IrisVision's groundbreaking technology worldwide. IrisVision's vision correction software platform utilizes the power of Samsung's industry leading Galaxy smartphones and XR devices and mobile AI platform to enable people with impaired vision to see clearly and live more independent lives, according to the announcement on Tuesday.
By Staff
Thursday, December 19, 2019 12:15 AM
BALTIMORE—
Versant Health, a leading national managed eye health and vision plan group, announced that it has designated December as Gift of Sight Month. The vision care company noted that it had decided to establish the “holiday” after a Vision Wellness Study found that just 51 percent of people saw an eye doctor regularly. The same study also noted that 39 percent of consumers cited cost and/or affordability as the reason why household members do not see an eye doctor as often as they would like to.
By Staff
Thursday, December 12, 2019 12:15 AM
MANASSAS, Va.—
Notal Vision Inc., a privately held ophthalmic diagnostic services company focused on advancing eyecare with precision medicine, said this week that
Ganot Capital is extending a recent funding round to $25 million. The continued investment will enable Notal Vision to support the commercial growth of the company’s current service, ForeseeHome AMD Monitoring Program, as well as further research and development efforts for pipeline technologies, according to the announcement. “Pursuing additional funding has allowed us to expand our ForeseeHome field-based sales team,” chief executive officer Kester Nahen said in the announcement. “We have a proven model that includes low-cost medical devices, an effective artificial intelligence (AI)-driven decision support solution, and a dependable clinical patient engagement platform. With the additional investment, we believe we will be able to prove that partnering with accounts as an extension of their practice will drive deeper adoption of our home diagnostic services.”
By Staff
Friday, July 20, 2018 12:15 AM
FARMINGTON, Conn. and MIDDLETOWN, Pa.—
Horizon Technology Finance Corp. (NASDAQ: HRZN), a leading specialty finance company, has led a $10 million loan facility for
MacuLogix Inc., according to an announcement earlier this week. Horizon, based in Farmington, typically provides capital in the form of secured loans to venture capital backed companies in the technology, life science and health care information and services sectors. MacuLogix, a medical device company, manufactures the AdaptDx automated dark adaptometer, a device that allows eyecare professionals to measure retinal function to accurately diagnose age-related macular degeneration (AMD). AMD is the leading cause of irreversible blindness in adults, according to the announcement.